cystic fibrosis | mecfa 21/28

MECFA Blog

Cystic Fibrosis Treatment Approved for Use in Children Aged 2 to 5 Years

Officials with the FDA have updated the label of lumacaftor/ivacaftor (Orkambi, Vertex Pharmaceuticals), approving the treatment's use in...

Gene Mutations Linked to Other Lung Diseases May Contribute to Bronchiectasis, Study Suggests

Mutations in genes linked to other lung diseases, specifically cystic fibrosis and primary ciliary dyskinesia, may also contribute to...

Arcturus’ RNA Therapy for CF Shows Promise in Preclinical Studies, Company Announces

Arcturus Therapeutics’ RNA-based approach enables the production of healthy CFTR— the protein whose dysfunction is key in cystic fibrosis...

AIT’s Inhaled Nitric Oxide Shows Potential in Fighting Bacterial Infection Prevalent in CF Patients

Inhaled nitric oxide (NO) was shown to be an effective antibacterial agent against Mycobacterium abscessus infection in preclinical...

New Method to Deliver Bacteria-killing Viruses Seen to Resolve Lung Infections in CF Mice

A new therapy which is administered directly into the lung of viruses can kill bacteria, and was shown to be effective in reducing...

Harmful Bacteria Replace Beneficial Ones in Gut of CF Patients, Study Finds

Cystic fibrosis (CF) patients have a higher amount of harmful gut bacteria and increased levels of intestinal inflammation than healthy...

Triclosan, often maligned, may have a good side — treating cystic fibrosis infections

Maybe you’ve had the experience of wading in a stream and struggling to keep your balance on the slick rocks, or forgetting to brush your...

Vertex, NHS England no closer to Orkambi settlement

Vertex and NHS England remain locked in a battle over the provision of cystic fibrosis drug Orkambi, seemingly no closer to a settlement...

Azithromycin Reduced Pulmonary Exacerbation Risk in Cystic Fibrosis

Azithromycin significantly reduced the risk for pulmonary exacerbations and resulted in sustained improvement in weight but had no effect...

Nanoparticles Therapy May Be ‘One-Size-Fits-All’ Approach for CF, Study Suggests

A potential therapy delivered through nanoparticles enables production of the normal, healthy form of the key CFTR protein in cystic...

Disease Duration, Flare-ups Affect Mental Health of Non-CF Bronchiectasis Patients, Study Finds

VERTEX’S CF BLOCKBUSTER TRIKAFTA EFFECTIVE IN KIDS 6 TO 11 YEARS OF AGE

A case for improved carrier screening

Vertex to Seek Expanded FDA Approval for Trikafta After Positive Child Safety Data

Vertex’s Kaftrio approved for use in Europe and made accessible on the NHS

Age May Affect Outcomes in Lung Transplant Recipients With Cystic Fibrosis

CFF Funding Will Further ContraFect’s Research Into Alternative for Antibiotics

The search for molecular glue in targeted disease control

Vest Therapy Lowers Risk of Hospitalization in Non-CF Bronchiectasis, Study Says

Harvard is working with Boston hospitals to test existing cystic fibrosis drug to help coronavirus p